Germitec, a leading medical technology company specializing in UV-C High-Level Disinfection solutions, announced the closing of a $30 million financing round. This funding will enable the company to accelerate its development in the U.S. market and continue pioneering advancements in UV-C infection prevention technologies.
Prominent European investment group Eurazeo led the funding round through its Nov Santé Actions Non Cotées fund, a platform supporting healthcare companies and innovation. And existing shareholders also participated in the round, demonstrating their confidence in Germitec’s vision and growth trajectory. Combined with prior funding from the European Investment Bank in 2023, this financing positions Germitec for sustained growth over the next two years, with profitability on the horizon.
Germitec’s flagship product line provides healthcare facilities fast, effective, and chemical-free solutions to prevent Healthcare-Associated Infections and improve the standard of care. And with global demand for infection prevention on the rise, Germitec’s solutions are positioned to address critical needs everywhere ultrasounds are performed: Fertility (IVF), gynecology, cardiology, ENT, and other specialties. Due to its UV-C technology and its availability in 40 countries, 2.2 million patients are protected across the world every year.
With an FDA De Novo granted in August 2024 and a market opportunity of 60,000 units in the U.S., Germitec is prepared to capture market share and double its revenue every year quickly.
The proceeds from this funding round will be allocated to scaling U.S. operations, accelerating commercial adoption and investing in research and development to expand Germitec’s product portfolio. The company aims to set new standards for disinfection efficiency and safety in the healthcare industry.
As Germitec grows, its mission remains clear: To provide state-of-the-art UV-C High-Level Disinfection technologies that protect patients and healthcare professionals alike.
KEY QUOTES:
“We are thrilled to welcome Eurazeo as a strategic investor and are equally grateful for the continued support from our existing shareholders. This funding marks a significant milestone for Germitec as we expand our footprint in the U.S. and maintain our commitment to developing cutting-edge disinfection solutions that enhance patient safety and operational efficiency.”
- Vincent Gardès, Chief Executive Officer of Germitec
“One of Eurazeo’s key pillars is to invest in major public health challenges. We are therefore extremely proud to support Germitec with its UV-C High-Level Disinfection solutions for ultrasound probes, and its mission to revolutionize infection prevention. Germitec’s innovative UV-C technology aligns with our commitment to foster transformative healthcare solutions that improve patient outcomes and system sustainability.”
- Arnaud Vincent, Managing Director – Healthcare, Eurazeo
